anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To suppress proliferation of Ieukocyte without causing adverse effect such as sunburn-like reaction by use of hypericin in a low concentration by administering a composition containing a hypericin derivative to mammal and photoactivating the hypericin derivative. SOLUTION: A composition containing a hypericin derivative is administered to Leukocyte group of mammal (e.g. human) having leukocyte-associated diseases or hindrance (e.g. psoriasis) by a method of oral administration, local administration, etc., and the hypericin derivative is photoactivated to suppress proliferation or accumulation of leukocyte. Hypericin of formula I, protohypericin of formula II, pseudohypericin of formula III, etc., is exemplified as the hypericin derivative. A method irradiating visible light or UV-A light which is preferably a light having about 500-650 nm wavelength is preferably used as the method for photoactivating the hypericin derivative.
Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have \~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.
OBJECTIVE: Proper nutrition is a significant contributor to growth achievement in patients with juvenile idiopathic arthritis (JIA). In this study, the aim was to analyze the growth parameters and nutritional status of children with JIA and then compare them with their healthy peers.
METHODS: A cross-sectional study was conducted with 54 patients with JIA and the same number of healthy peers. Growth parameter z-scores and nutrient distributions were analyzed and compared with a control group and among disease subgroups.
RESULTS: While the average height in the control group was significantly greater than in the patient group, there was similarity in terms of body weight and body mass index (BMI) (P < 0.001, P = 0.33, P = 0.14, respectively). Body weight and BMI z-scores of patients with high disease activity at the most recent visit were significantly lower (P = 0.03, P = 0.01, respectively). Both groups had similar energy and protein requirement-meeting percentages (P = 0.62, P = 0.51). JIA atients had higher carbohydrate intake (P = 0.04), and fat intake was higher in controls (P = 0.02). Energy obtained from junk food was higher in patients with entesitis-related arthritis (ERA) compared to oligoarticular JIA and polyarticular JIA (P = 0.03). Micronutrient intake in the ERA group was significantly lower for vitamin E, C, and folate (P = 0.02, P = 0.03, P < 0.001).
CONCLUSION: In our cohort, patients had a lower height score. As they have a diet characterized by adequate energy/protein, carbohydrate, and high fat intake, this may be a reflection of disease activity. Although some of the micronutrient intakes were less than normal in both groups, significant deficiencies were identified in the ERA group.
EpiPen® and EpiPen® Jr Auto-Injectors are not intended as a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision. 

Epinephrine is essential for the treatment of anaphylaxis. Patients with a history of severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs, and other allergens as well as idiopathic and exercise-induced anaphylaxis should be carefully instructed about the circumstances under which epinephrine should be used. It must be clearly determined that the patient is at risk of future anaphylaxis, since the following risks may be associated with epinephrine administration (see DOSAGE and ADMINISTRATION). 

Epinephrine should be used with caution in patients who have cardiac arrhythmias, coronary artery or organic heart disease, hypertension, or in patients who are on drugs that may sensitize the heart to arrhythmias, e.g., digitalis, diuretics, quinidine, or other antiarrhythmics. In such patients, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias. 

The effects of epinephrine may be potentiated by tricyclic antidepressants and monoamine oxidase inhibitors. 

Some patients may be at greater risk of developing adverse reactions after epinephrine administration. These include: hyperthyroid individuals, individuals with cardiovascular disease, hypertension, or diabetes, elderly individuals, pregnant women, pediatric patients under 30 kg (66 lbs.) body weight using EpiPen® Auto-Injector, and pediatric patients under 15 kg (33 lbs.) body weight using EpiPen® J r Auto-Injector. 

Despite these concerns, epinephrine is essential for the treatment of anaphylaxis. Therefore, patients with these conditions, and/or any other person who might be in a position to administer EpiPen® or EpiPen® Jr Auto-Injector to a patient experiencing anaphylaxis should be carefully instructed in regard to the circumstances under which epinephrine should be used.
PURPOSE:To obtain sustained release granules continuing release of a drug for a long time, producible by a relatively simple method, comprising an ethanol- insoluble water-soluble high polymer substance and an ethanol-soluble water-soluble high polymer substance as bases. CONSTITUTION:Sustained release granules containing (A) a drug such as an anti-inflammatory drug (e.g. indomethacin), antihistamine agent (e.g. diphenyl pyraline) or vitamins, (B) an ethanol-insoluble water-soluble high polymer sub stance such as CMC-Na, PVA or sodium alginate and (C) an ethanol-soluble high polymer substance such as hydroxypropyl cellulose or polyvinyl pyrrolidone. The blending ratio is 1-50pts.wt., preferably 2-35pts.wt. component C based on 100pts.wt. component B. The granules can be produced by uniformly blending the three components, adding ethanol, uniformly wetting, extruding and granulat ing.
Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
FIELD: medicine. SUBSTANCE: method involves alkaline treatment of hydrolytic lignin, preparing alkaline lignin suspension, washing off lignin with water, separation of washing water, neutralization with acid, separation of acidic filtrate, lignin washing off with water from acid excess, separation of washing water and lignin milling. Before lignin washing off with water from alkaline excess an alkaline suspension is separated on static electroosmotic filter by air effect. Air is fed under pressure 380-500 kPa in direct current field at field intensity (5-10) x 10V/m and current power 100-150 A. Process of lignin alkaline suspension separation is carried out at 60-70 C for 15-20 min, duration of field effect is 1-5 min. EFFECT: improved method of lignin preparing. 8 cl
PURPOSE: Obstructive Sleep Apnea (OSA) is the most common sleep-related disorder. Interoception is the collection of sensory and cognitive processes that involve receiving and interpreting physiological signals from internal body structures and conveying the perception of inner sensations. In this study, it was hypothesized that the impairment in cognitive functions associated with chronic hypoxemia and the insular effects due to OSA would negatively affect interoceptive functions. The aim of this study was to evaluate whether interoception in OSA changes consistent with the hypothesis.
METHODS: A total of 102 patients diagnosed with OSA were included in this study. All participants were divided into groups based on their T90 values: desaturated OSA (T90 ≥ 20%) and non-desaturated OSA (T90 < 20%). The Heartbeat Counting Task was used to assess interoceptive accuracy, while the Interoceptive Sense Questionnaire (ISQ) was employed to identify subjective challenges in evaluating interoception.
RESULTS: Interoceptive accuracy was lower in the desaturated OSA group than in the non-desaturated OSA group (Z = -2.463; p = 0.014). Interoceptive accuracy was negatively correlated with the body mass index (r = -0.228; p = 0.021), T90 (r = -0.269; p = 0.006), and positively correlated with the average SaO2 (r = 0.377; p < 0.001) and SaO2 nadir (r = 0.243; p = 0.014).
CONCLUSION: This study examined interoceptive functions in patients with OSA. It was concluded that interoceptive accuracy is affected by the severity of hypoxia as hypothesized.
The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
The invention relates to a sulfoxide-based alkane isothiocyanate optical isomer and an application thereof in preparation of drugs, wherein the sulfoxide-based alkane isothiocyanate optical isomer is prepared through inclusion resolution and stereo selective oxidation reaction. The sulfoxide-based alkane isothiocyanate optical isomer has different tumor inhibition and bacterial pharmacological activities. The compound can be used alone or be used together with other drugs with effects of treating a plurality of diseases. The compound can be used for treating a variety of cancers, eliminating inflammation and realizing oxidation resistance and skin light protectiveness and the like. The formulations of the drug comprise tablets, buccal tablets, capsules, soft capsules, granules, syrup, micro-pills, micro-spheres, pills, aqua and the like. The compound can be prepared into different administration ways comprising intravenous way, oral administration, subcutaneous way, intra-arterial administration or topical administration way for treating patients.
PURPOSE:To provide a nutrition-promoting medicine containing oligopeptide as an active component and effective in lowering ammonia level in blood and urine. CONSTITUTION:A nutrition-promoting medicine capable of effectively lowering the ammonia level in blood and the amount of ammonia secreted in urine without causing malnutrition, etc., is produced by adding >=5wt% oligopeptide (preferably having an average molecular weight of 360-2,000 and average chain length of 2-10) produced by the enzymatic hydrolysis of protein or a protein-containing substance as a nitrogen source to a nutrition-promoting agent and properly adding a lipid (e.g. vegetable or animal oil or fat, etc.), saccharide (e.g. cellulose, starch, dextrin, etc.) and other compound (e.g. vitamins, minerals, etc.) which is essential or desirable to take from nutritional point of view. A partial hydrolyzate of protein containing low-molecular-weight peptide is subjected to plastein reaction and the resynthesized polypeptide can be used as the above oligopeptide.
Despite major advances in the treatment of psychiatric disorders, Hispanics continue to underutilize mental health services relative to their own mental health needs. Cultural factors are important causes of underutilization. To date, however, attempts to boost utilization by improving the cultural congruence of psychiatric services have not focused on retaining Hispanics in antidepressant therapy.

Motivational Interviewing (MI) is a time-limited psychotherapy that has successfully improved treatment retention among patients with dually diagnosed substance abuse and psychiatric disorders. During Phase I of this study, MI is adapted for use as an adjunctive therapy with antidepressant treatment and culturally adapted to Hispanic participants. In Phase II, participants receive sertraline for 12 weeks and participate in four sessions of MI therapy as a supplementary intervention designed to encourage treatment retention. Participants who are intolerant to sertraline or have an inadequate response by Week 6 are switched to venlafaxine ER while continuing to receive MI and to complete study assessments. A follow-up interview is conducted 6 months after the termination of treatment.
Anaphylaxis and other systemic reactions may occur such as induced asthma, itching of nose and throat, breathlessness, urticaria and local reactions. Local reactions can be defined as an area of large erythema, swelling or pruritus at the injection site. Further indications of adverse reactions are edema, wheezing, dyspnea, locomotive impairment, marked perspiration, coughing, hypertension, shock and upper airway obstruction.

Adverse systemic reactions usually occur within minutes and consist primarily of allergic symptoms such as generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema and hypotension. Less commonly, nausea, emesis, abdominal cramps, diarrhea and uterine contractions may occur. Severe reactions may cause shock and loss of consciousness. Fatalities have occurred rarely. These systemic reactions occur with varying frequency in different clinics. To some extent, the reaction rate is related to the type and dose of administered extract and to the degree of sensitivity of the patient. Despite all precautions, occasional reactions are unavoidable. 

Reports from regulatory authorities in Sweden to the Center for Biologics Evaluation and Research (CBER) indicated that several deaths have been associated with the use of mite extracts. The CBER was subsequently informed that these deaths may have been related to use by physicians or other health professionals untrained in the administration of potent allergens rather than a product defect. It should be noted that anaphylaxis and deaths following the injection of mite extracts have also been reported by the British Committee on Safety in Medicine in the British Medical Journal, V293,pp948,1986. 

Local reactions consisting of erythema, itching, swelling tenderness and sometimes pain may occur at the injection site. These reactions may appear within a few minutes to hours and persist for several days. Local cold applications and oral antihistamines may be effective treatment. For marked and prolonged local reactions steroids may be helpful.
A system for managing health-related issues (e.g., diabetes) includes a measurement device for measuring a health characteristic and a processing device communicatively connected to the measurement device. The processing device receives the measurement results from the measurement device. The processing device includes a processor, a user interface, and at least one memory device. The at least one memory device stores one or more measurements and stores computer-readable instructions for a healthcare application. The processor executes a healthcare application. The healthcare application displays and receives supplemental health data associated with the one or more measurements via the user interface. The healthcare application allows the user to enter supplemental data based on compliance flare tips, measurement and record instructions, retrospective records, and/or data displays utilizing an electronic calendar. The healthcare application may prompt the user to take measurements and enter supplemental data according to these features.
After the patients in the experimental group were informed verbally and in writing and consented to participate in the study, the Patient Information Form, the Piper Fatigue Scale (PFS), and the Pittsburgh Sleep Quality Index (PSQI) were applied in the first interview and the initial readings were obtained. The researcher received training on a classical massage from an expert massage therapist before the foot massaging application. Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI.
The combined effect of cardiovascular risk factors on breast cancer in women is unknown. The relationship between genetic risk combined with cardiovascular health (CVH) levels and breast cancer has not been confirmed. This study aims to explore the relationship between CVH level based on life's essential 8 (LE8) score and breast cancer risk in women with different menopausal statuses and to estimate further the effect of CVH level combined with genetic susceptibility on breast cancer risk. A total of 118,911 women from UK Biobank were included in the study, including 22,676 premenopausal women and 96,235 postmenopausal women. The association between the CVH level and the risk of breast cancer in women with different menopausal statuses was assessed using the Cox proportional hazards regression models, with the healthiest CVH group as the reference. In addition, risk ratios (HRs) and 95% confidence intervals (95% CIs) for the joint effect of the CVH level and polygenic risk score (PRS) were calculated using the PRS from the UK Biobank. During a mean follow-up period of 13.8 years, we observed 733 cases and 3,645 cases of breast cancer in premenopausal and postmenopausal women, respectively. In premenopausal women, the risk of breast cancer was significantly increased in the intermediate CVH group (HR, 1.28; 95%CI 1.08-1.52) and the low CVH group (HR, 1.44; 95%CI 1.13-1.85). In postmenopausal women, the risk of incidence was also significantly increased in the intermediate CVH group (HR, 1.20; 95%CI 1.07-1.32) and the low CVH group (HR, 1.34; 95%CI 1.17-1.54). In the joint effect analysis, the risk of breast cancer for women in the low CVH group and the high genetic risk group was highest in both premenopausal (HR, 8.26; 95%CI 4.44-15.35) and postmenopausal (HR, 8.10; 95%CI 5.50-11.93) women. Women with lower LE8 scores and higher genetic susceptibility have the higher risk of breast cancer. This suggests that women with lower levels of CVH and higher genetic susceptibility have an increased risk of breast cancer under different menopausal statuses.
PROBLEM TO BE SOLVED: To impart to human cells an improved sensitivity to nucleoside analogue by employing a specific kind of thymidinekinase. SOLUTION: This method is to contact human cells with an Equine herpes virus type-4 thymidinekinase (EHV4-TK).polypeptide or a nucleic acid coding therefor in vitro, ex vivo or in vivo. In an in vitro or ex vivo use, cells to be treated preferably are cultured in an optional device (e.g. a plate or the like) under an aseptic condition in a conventional medium (e.g. RPMI medium, or the like) and are contacted with a vector containing the EHV4- TK.polypeptide or a nucleic acid coding therefor. In an in vivo practice, the EHV4-TK.polypeptide or a nucleic acid coding therefor is administered directly to an object needed to be treated in such a way as to contact with cells.
PURPOSE:To provide a new compound having a 5-HT3-antagonizing activity and useful as an antiemetic agent and its synthetic intermediate. CONSTITUTION:A compound of formula I, e.g. 6-amino-5-chloro-1-isopropyl-2(4-- methyl-1-piperazinyl) benzimidazole. The compound of formula I is obtained by reacting a compound of formula II with a reducing agent (e.g. zinc- hydrochloric acid) in an amount of 4-7 equivalents per equivalent of the compound of formula II at room temperature to the refluxing temperature for 1-10hrs. The compound of formula I has a strong antagonistic activity against a Bezold-Jarisch reflex derived from 5-HT, and the activity is persisted for a long time. The compound of formula I exhibits a strong and persistent inhibiting activity against emeses derived by cisplatin and is lowly toxic and highly safe.
The project's long-term goal is to improve the mental health of Mexican-origin youth by reducing the deleterious effects of racism, "othering," and negative neighborhood interactions. Community based collaboration will be used to recruit a sample of 340 Mexican-origin adolescents, mothers, and fathers in Indiana. The inclusion of fathers will be a valuable contribution to the literature, given the dearth of studies on Latinx fathers/stepfathers. A combination of annual surveys administered over three waves to parents and youth ("macro-time") and a 21-day daily diary ("micro-time") administered in wave 1 to youth is employed to assess important questions about how mediating and moderating processes unfold over time. Specific aims of the project include determination of within-person discrimination-related stressors that impact youth's mental health outcomes and the mechanisms of action at both micro- and macro- time levels; identification of protective factors that could help coping with discrimination related stressors and conditions under which they work; and elucidating youth, parent, and neighborhood risk factors that moderate the link between discrimination-related stressors and mental health outcomes in youth. This research is highly translational in that it will facilitate the development of more effective, culturally sensitive prevention and intervention strategies for Latinx youth and their families.
Participants who received a single dose of Menomune vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
INTRODUCTION: Iatrogenic cerebral amyloid angiopathy (iCAA) is a rare form of CAA. Imaging features are overlapping with spontaneous CAA. However, in iCAA imaging features have not been systematically described so far. The aim of this metaanalysis was to evaluate if any of the described imaging features showed colocalization with the initial site of surgery.
MATERIAL AND METHODS: A systematic review of the medical literature was performed. Patients with probable iCAA were included if the route of potential entry of amyloid into the CNS was unambiguous.
RESULTS: 24 patients from 19 reports could be included. 84 ICHs were reported. 11 of the first ever ICH (69%, p = 0.0498, Fisher's exact test) occurred ipsilateral to the site of the initial surgery, whereas 59% of all ICH (n = 63, p = 0.126, Fisher's exact test) occurred ipsilateral to the site of the initial surgery. No cerebellar hemorrhages (0%) were reported. In 5 of 8 patients, ipsilateral hemorrhagic and non-hemorrhagic manifestations were present before symptom onset and/or occurrence of ICH.
DISCUSSION: This metananalysis of the imaging markers of iCAA revealed a spatial colocalization of first ICH with the site of the surgery. Imaging studies with patients at risk for iCAA after exposure to lyophilized dura should be conducted.